1
|
Ahmad I, Patel HM. Repurposing Non-Nucleosidic Reverse Transcriptase Inhibitors (NNRTIs) to Overcome EGFR T790M-Mediated Acquired Resistance in Non-Small Cell Lung Cancer. J Cell Biochem 2024:e30653. [PMID: 39300843 DOI: 10.1002/jcb.30653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2024] [Revised: 08/29/2024] [Accepted: 09/05/2024] [Indexed: 09/22/2024]
Abstract
This study investigates the repurposing potential of non-nucleosidic reverse transcriptase inhibitors (NNRTIs), specifically Rilpivirine and Etravirine, as L858R/T790M tyrosine kinase inhibitors for addressing acquired resistance in non-small cell lung cancer (NSCLC). Using in silico molecular docking, Rilpivirine demonstrated a docking score of -7.534 kcal/mol, comparable to established epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) like Osimertinib and WZ4002. Molecular dynamics (MD) simulations over 200 ns revealed the stability of the Rilpivirine-EGFR complex, with RMSD values ranging from 2.5 to 3.5 Å. The in vitro antiproliferative assays showed that Rilpivirine had an IC50 value of 2.3 µM against H1975 cells, while WZ4002 had an IC50 of 0.291 µM, indicating moderate efficacy. Enzymatic assays revealed that Rilpivirine inhibited the double mutant epidermal growth factor receptor tyrosine kinase (EGFR TK) with an IC50 value of 54.22 nM and spared the wild-type EGFR TK with an IC50 of 22.52 nM. These findings suggest Rilpivirine's potential as a therapeutic agent for NSCLC with EGFR L858R/T790M mutations.
Collapse
Affiliation(s)
- Iqrar Ahmad
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India
| | - Harun M Patel
- Department of Pharmaceutical Chemistry, R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Maharashtra, India
| |
Collapse
|
2
|
Kageji H, Momose T, Ebisawa M, Nakazawa Y, Okada H, Togashi N, Nagamoto Y, Obuchi W, Yasumatsu I, Kihara K, Hiramoto K, Minami M, Kasanuki N, Isoyama T, Naito H, Tanaka N. Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity. Bioorg Med Chem 2024; 111:117862. [PMID: 39111073 DOI: 10.1016/j.bmc.2024.117862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2024] [Revised: 07/23/2024] [Accepted: 07/25/2024] [Indexed: 08/24/2024]
Abstract
The C797S mutation is one of the major factors behind resistance to the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Herein, we describe the discovery of DS06652923, a novel, potent, and orally available EGFR-triple-mutant inhibitor. Through scaffold hopping from the previously reported nicotinamide derivative, a novel biaryl scaffold was obtained. The potency was successfully enhanced by the introduction of basic substituents based on analysis of the docking study results. In addition, the difluoromethoxy group on the pyrazole ring improved the kinase selectivity by inducing steric clash with the other kinases. The most optimized compound, DS06652923, achieved tumor regression in the Ba/F3 allograft model upon its oral administration.
Collapse
Affiliation(s)
- Hideaki Kageji
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
| | - Takayuki Momose
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Masayuki Ebisawa
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Yusuke Nakazawa
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Hiroyuki Okada
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Noriko Togashi
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Yasuhito Nagamoto
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Wataru Obuchi
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Isao Yasumatsu
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Kawori Kihara
- Daiichi Sankyo Co., Ltd., 2716-1 Chiyodamachi, Oaza Akaiwa, Aza Kurakake, Oura, Gunma 370-0503, Japan
| | - Kumiko Hiramoto
- Daiichi Sankyo Co., Ltd., 2716-1 Chiyodamachi, Oaza Akaiwa, Aza Kurakake, Oura, Gunma 370-0503, Japan
| | - Megumi Minami
- Daiichi Sankyo Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan
| | - Naomi Kasanuki
- Daiichi Sankyo Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan
| | - Takeshi Isoyama
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Hiroyuki Naito
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Naoki Tanaka
- Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| |
Collapse
|
3
|
Halder P, Rai A, Talukdar V, Das P, Lakkaniga NR. Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy. RSC Med Chem 2024; 15:1452-1470. [PMID: 38784451 PMCID: PMC11110789 DOI: 10.1039/d4md00003j] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Accepted: 03/24/2024] [Indexed: 05/25/2024] Open
Abstract
The need for effective cancer treatments continues to be a challenge for the biomedical research community. In this case, the advent of targeted therapy has significantly improved therapeutic outcomes. Drug discovery and development efforts targeting kinases have resulted in the approval of several small-molecule anti-cancer drugs based on ATP-mimicking heterocyclic cores. Pyrazolopyridines are a group of privileged heterocyclic cores in kinase drug discovery, which are present in several inhibitors that have been developed against various cancers. Notably, selpercatinib, glumetinib, camonsertib and olverembatinib have either received approval or are in late-phase clinical studies. This review presents the success stories employing pyrazolopyridine scaffolds as hinge-binding cores to address various challenges in kinase-targeted drug discovery research.
Collapse
Affiliation(s)
- Pallabi Halder
- Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines) Dhanbad India
| | - Anubhav Rai
- Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines) Dhanbad India
| | - Vishal Talukdar
- Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines) Dhanbad India
| | - Parthasarathi Das
- Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines) Dhanbad India
| | - Naga Rajiv Lakkaniga
- Department of Chemistry and Chemical Biology, Indian Institute of Technology (Indian School of Mines) Dhanbad India
| |
Collapse
|
4
|
Laudadio E, Mangano L, Minnelli C. Chemical Scaffolds for the Clinical Development of Mutant-Selective and Reversible Fourth-Generation EGFR-TKIs in NSCLC. ACS Chem Biol 2024; 19:839-854. [PMID: 38552205 DOI: 10.1021/acschembio.4c00028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/20/2024]
Abstract
In nonsmall cell lung cancer (NSCLC), as well as in other tumors, the targeted therapy is mainly represented by tyrosine kinase inhibitors (TKIs), small molecules able to target oncogenic driver alterations affecting the gene encoding the epidermal growth factor receptor (EGFR). Up to now, several different TKIs have been developed. However, cancer cells showed an incredible adaptive tumor response to the inhibition of the sequentially mutated EGFR (EGFRM+), triggering the need to explore novel pharmacochemical strategies. This Review summarizes the recent efforts in the development of new reversible next-generation EGFR TKIs to fight the resistance against T790M and C797S mutations. Specifically, after giving an overview of the role of the EGFR's signaling pathways in cancer progression, we are going to discuss the most relevant approved drugs and drug candidates in terms of chemical structure, binding modalities, and their potency and selectivity against the mutated EGFR over the wild-type form. This could provide important guidelines and rationale for the discovery and iterative development of new drugs.
Collapse
Affiliation(s)
- Emiliano Laudadio
- Department of Science and Engineering of Matter, Environment and Urban Planning, Marche Polytechnic University, 60131 Ancona, Italy
| | - Luca Mangano
- Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, 4070 Basel, Switzerland
| | - Cristina Minnelli
- Department of Life and Environmental Sciences, Marche Polytechnic University, 60131 Ancona, Italy
| |
Collapse
|
5
|
Kageji H, Momose T, Nagamoto Y, Togashi N, Yasumatsu I, Nishikawa Y, Kihara K, Hiramoto K, Minami M, Kasanuki N, Isoyama T, Naito H. Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutation. Bioorg Med Chem Lett 2024; 98:129575. [PMID: 38065292 DOI: 10.1016/j.bmcl.2023.129575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2023] [Revised: 11/23/2023] [Accepted: 12/02/2023] [Indexed: 12/23/2023]
Abstract
The C797S mutation is one of the major factors behind resistance to the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Herein, we describe the discovery of the 2,4-diaminonicotinamide derivative 5j, which shows potent inhibitory activity against EGFR del19/T790M/C797S and L858R/T790M/C797S. We also report the structure-activity relationship of the 2,4-diaminonicotinamide derivatives and the co-crystal structure of 5j and EGFR del19/T790M/C797S.
Collapse
Affiliation(s)
- Hideaki Kageji
- R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
| | - Takayuki Momose
- R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Yasuhito Nagamoto
- R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Noriko Togashi
- R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Isao Yasumatsu
- Daiichi Sankyo RD Novare Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Yosuke Nishikawa
- Daiichi Sankyo RD Novare Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Kawori Kihara
- Daiichi Sankyo RD Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan
| | - Kumiko Hiramoto
- Daiichi Sankyo RD Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan
| | - Megumi Minami
- Daiichi Sankyo RD Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan
| | - Naomi Kasanuki
- Daiichi Sankyo RD Novare Co., Ltd., 1-16-13 Kitakasai, Edogawa-ku, Tokyo 134-8630, Japan
| | - Takeshi Isoyama
- R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| | - Hiroyuki Naito
- R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan
| |
Collapse
|
6
|
Peytam F, Emamgholipour Z, Mousavi A, Moradi M, Foroumadi R, Firoozpour L, Divsalar F, Safavi M, Foroumadi A. Imidazopyridine-based kinase inhibitors as potential anticancer agents: A review. Bioorg Chem 2023; 140:106831. [PMID: 37683538 DOI: 10.1016/j.bioorg.2023.106831] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 08/16/2023] [Accepted: 08/30/2023] [Indexed: 09/10/2023]
Abstract
Considering the fundamental role of protein kinases in the mechanism of protein phosphorylation in critical cellular processes, their dysregulation, especially in cancers, has underscored their therapeutic relevance. Imidazopyridines represent versatile scaffolds found in abundant bioactive compounds. Given their structural features, imidazopyridines have possessed pivotal potency to interact with different protein kinases, inspiring researchers to carry out numerous structural variations. In this comprehensive review, we encompass an extensive survey of the design and biological evaluations of imidazopyridine-based small molecules as potential agents targeting diverse kinases for anticancer applications. We describe the structural elements critical to inhibitory potency, elucidating their key structure-activity relationships (SAR) and mode of actions, where available. We classify these compounds into two groups: Serine/threonine and Tyrosine inhibitors. By highlighting the promising role of imidazopyridines in kinase inhibition, we aim to facilitate the design and development of more effective, targeted compounds for cancer treatment.
Collapse
Affiliation(s)
- Fariba Peytam
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Zahra Emamgholipour
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Alireza Mousavi
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Mahfam Moradi
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Roham Foroumadi
- Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Loghman Firoozpour
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Divsalar
- Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
| | - Maliheh Safavi
- Department of Biotechnology, Iranian Research Organization for Science and Technology, Tehran, Iran
| | - Alireza Foroumadi
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Neuroscience Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran; Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
7
|
Das AP, Nandekar P, Mathur P, Agarwal SM. A systematic pipeline of protein structure selection for computer-aided drug discovery: A case study on T790M/L858R mutant EGFR structures. Protein Sci 2023; 32:e4740. [PMID: 37515373 PMCID: PMC10443354 DOI: 10.1002/pro.4740] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2023] [Revised: 07/24/2023] [Accepted: 07/26/2023] [Indexed: 07/30/2023]
Abstract
Virtual screening (VS) is a routine method to evaluate chemical libraries for lead identification. Therefore, the selection of appropriate protein structures for VS is an essential prerequisite to identify true actives during docking. But the presence of several crystal structures of the same protein makes it difficult to select one or few structures rationally for screening. Therefore, a computational prioritization protocol has been developed for shortlisting crystal structures that identify true active molecules with better efficiency. As identification of small-molecule inhibitors is an important clinical requirement for the T790M/L858R (TMLR) EGFR mutant, it has been selected as a case study. The approach involves cross-docking of 21 co-crystal ligands with all the structures of the same protein to select structures that dock non-native ligands with lower RMSD. The cross docking performance was then correlated with ligand similarity and binding-site conformational similarity. Eventually, structures were shortlisted by integrating cross-docking performance, and ligand and binding-site similarity. Thereafter, binding pose metadynamics was employed to identify structures having stable co-crystal ligands in their respective binding pockets. Finally, different enrichment metrics like BEDROC, RIE, AUAC, and EF1% were evaluated leading to the identification of five TMLR structures (5HCX, 5CAN, 5CAP, 5CAS, and 5CAO). These structures docked a number of non-native ligands with low RMSD, contain structurally dissimilar ligands, have conformationally dissimilar binding sites, harbor stable co-crystal ligands, and also identify true actives early. The present approach can be implemented for shortlisting protein targets of any other important therapeutic kinases.
Collapse
Affiliation(s)
- Agneesh Pratim Das
- Bioinformatics Division, ICMR—National Institute of Cancer Prevention and ResearchNoidaUttar PradeshIndia
- Amity Institute of BiotechnologyAmity University Uttar PradeshNoidaUttar PradeshIndia
| | | | - Puniti Mathur
- Amity Institute of BiotechnologyAmity University Uttar PradeshNoidaUttar PradeshIndia
| | - Subhash M. Agarwal
- Bioinformatics Division, ICMR—National Institute of Cancer Prevention and ResearchNoidaUttar PradeshIndia
| |
Collapse
|
8
|
Eno MS, Brubaker JD, Campbell JE, De Savi C, Guzi TJ, Williams BD, Wilson D, Wilson K, Brooijmans N, Kim J, Özen A, Perola E, Hsieh J, Brown V, Fetalvero K, Garner A, Zhang Z, Stevison F, Woessner R, Singh J, Timsit Y, Kinkema C, Medendorp C, Lee C, Albayya F, Zalutskaya A, Schalm S, Dineen TA. Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer. J Med Chem 2022; 65:9662-9677. [PMID: 35838760 PMCID: PMC9340769 DOI: 10.1021/acs.jmedchem.2c00704] [Citation(s) in RCA: 61] [Impact Index Per Article: 30.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
![]()
While epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors
(TKIs) have changed the treatment landscape for EGFR mutant (L858R
and ex19del)-driven non-small-cell lung cancer (NSCLC), most patients
will eventually develop resistance to TKIs. In the case of first-
and second-generation TKIs, up to 60% of patients will develop an
EGFR T790M mutation, while third-generation irreversible TKIs, like
osimertinib, lead to C797S as the primary on-target resistance mutation.
The development of reversible inhibitors of these resistance mutants
is often hampered by poor selectivity against wild-type EGFR, resulting
in potentially dose-limiting toxicities and a sub-optimal profile
for use in combinations. BLU-945 (compound 30) is a potent,
reversible, wild-type-sparing inhibitor of EGFR+/T790M and EGFR+/T790M/C797S
resistance mutants that maintains activity against the sensitizing
mutations, especially L858R. Pre-clinical efficacy and safety studies
supported progression of BLU-945 into clinical studies, and it is
currently in phase 1/2 clinical trials for treatment-resistant EGFR-driven
NSCLC.
Collapse
Affiliation(s)
- Meredith S Eno
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Jason D Brubaker
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - John E Campbell
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Chris De Savi
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Timothy J Guzi
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Brett D Williams
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Douglas Wilson
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Kevin Wilson
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Natasja Brooijmans
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Joseph Kim
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Ayşegül Özen
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Emanuele Perola
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - John Hsieh
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Victoria Brown
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Kristina Fetalvero
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Andrew Garner
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Zhuo Zhang
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Faith Stevison
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Rich Woessner
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Jatinder Singh
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Yoav Timsit
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Caitlin Kinkema
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Clare Medendorp
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Christopher Lee
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Faris Albayya
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Alena Zalutskaya
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Stefanie Schalm
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Thomas A Dineen
- Blueprint Medicines, 45 Sidney Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
9
|
Mir SA, Nayak B. Exploring binding stability of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with T790M/L858R EGFR-TKD. J Biomol Struct Dyn 2022; 41:3702-3716. [PMID: 35343861 DOI: 10.1080/07391102.2022.2053748] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Cancer causes innumerable deaths every year globally. Breast cancer and non-small cell lung carcinoma are the most prevalent worldwide. EGFR-TKD is a neoplastic survival therapeutic target in a wide array of carcinoma cells. Various non-specific tyrosine kinase inhibitors lead to hyperphosphorylation and overexpression of EGFR-TKD and further mutations recognise deletion of exon 19. In this work, we study the binding affinity, binding stability, and strength of hydroxy-3-(4-hydroxyphenyl)-5-(4-nitrophenyl)-5,5a,7,8,9,9a-hexahydrothiazolo[2,3-b] quinazolin-6-one with TMLR mutated EGFR-TKD (T790M/L858R). The collective motions, residual mobility, and flexibility of TMLR mutated EGFR-TKD bound with reference and title molecule were calculated by principal component analysis. The meta-state conformations of both the simulated complexes were determined by Gibb's energy landscape analysis. The binding affinity exhibited by thiazolo-[2,3-b] quinazolinone and the reference molecule was found to be -7.95 ± 0.088 Kcal/mol and -9.13 ± 0.018 kcal/mol with TMLR mutated EGFR-TKD. The alignment of both the docked complexes was done by blosum40 matrix. Similar spatial orientations were exhibited by the synthesised ligand in the binding pocket of TMLR mutated EGFR-TKD, corresponding to the reference ligand. The ligand stability was computed for 100 ns. In addition, the radius of gyration, solvent accessible surface area, hydrogen bonds formed was calculated. The average ΔGbind of thiazolo-[2,3-b] quinazolinone was -41.212 ± 0.834 kJ/mol and for reference ligand -71.938 ± 0.367 kJ/mol, calculated by MM-PBSA. ADMET analysis concludes thiazolo-[2,3-b] quinazolinone derivative is safe. Further research work is encouraged to determine the efficacy of thiazolo-[2,3-b] quinazolinone against in vivo models.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
| | - Binata Nayak
- School of Life Sciences, Sambalpur University, Burla, Odisha, India
| |
Collapse
|
10
|
Filho EV, Pinheiro EM, Pinheiro S, Greco SJ. Aminopyrimidines: Recent synthetic procedures and anticancer activities. Tetrahedron 2021. [DOI: 10.1016/j.tet.2021.132256] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
|
11
|
Ward RA, Fawell S, Floc'h N, Flemington V, McKerrecher D, Smith PD. Challenges and Opportunities in Cancer Drug Resistance. Chem Rev 2020; 121:3297-3351. [PMID: 32692162 DOI: 10.1021/acs.chemrev.0c00383] [Citation(s) in RCA: 189] [Impact Index Per Article: 47.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
There has been huge progress in the discovery of targeted cancer therapies in recent years. However, even for the most successful and impactful cancer drugs which have been approved, both innate and acquired mechanisms of resistance are commonplace. These emerging mechanisms of resistance have been studied intensively, which has enabled drug discovery scientists to learn how it may be possible to overcome such resistance in subsequent generations of treatments. In some cases, novel drug candidates have been able to supersede previously approved agents; in other cases they have been used sequentially or in combinations with existing treatments. This review summarizes the current field in terms of the challenges and opportunities that cancer resistance presents to drug discovery scientists, with a focus on small molecule therapeutics. As part of this review, common themes and approaches have been identified which have been utilized to successfully target emerging mechanisms of resistance. This includes the increase in target potency and selectivity, alternative chemical scaffolds, change of mechanism of action (covalents, PROTACs), increases in blood-brain barrier permeability (BBBP), and the targeting of allosteric pockets. Finally, wider approaches are covered such as monoclonal antibodies (mAbs), bispecific antibodies, antibody drug conjugates (ADCs), and combination therapies.
Collapse
Affiliation(s)
- Richard A Ward
- Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | - Stephen Fawell
- Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States
| | - Nicolas Floc'h
- Bioscience, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| | | | | | - Paul D Smith
- Bioscience, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K
| |
Collapse
|
12
|
Cai Q, Zhou W. Ullmann‐Ma
Reaction: Development, Scope and Applications in Organic Synthesis
†. CHINESE J CHEM 2020. [DOI: 10.1002/cjoc.202000075] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Qian Cai
- College of Pharmacy, Jinan University No. 601 Huangpu Avenue West Guangzhou Guangdong 510632 China
| | - Wei Zhou
- College of Pharmacy, Jinan University No. 601 Huangpu Avenue West Guangzhou Guangdong 510632 China
| |
Collapse
|
13
|
Ayati A, Moghimi S, Salarinejad S, Safavi M, Pouramiri B, Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem 2020; 99:103811. [PMID: 32278207 DOI: 10.1016/j.bioorg.2020.103811] [Citation(s) in RCA: 189] [Impact Index Per Article: 47.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Revised: 03/15/2020] [Accepted: 03/29/2020] [Indexed: 12/14/2022]
Abstract
The identification of molecular agents inhibiting specific functions in cancer cells progression is considered as one of the most successful plans in cancer treatment. The epidermal growth factor receptor (EGFR) over-activation is observed in a vast number of cancers, so, targeting EGFR and its downstream signaling cascades are regarded as a rational and valuable approach in cancer therapy. Several synthetic EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in recent years, mostly exhibited clinical efficacy in relevant models and categorized into first, second, third and fourth-generation. However, studies are still ongoing to find more efficient EGFR inhibitors in light of the resistance to the current inhibitors. In this review, the importance of targeting EGFR signaling pathway in cancer therapy and related epigenetic mutations are highlighted. The recent advances on the discovery and development of different EGFR inhibitors and the use of various therapeutic strategies such as multi-targeting agents and combination therapies have also been reviewed.
Collapse
Affiliation(s)
- Adileh Ayati
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
| | - Setareh Moghimi
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
| | - Somayeh Salarinejad
- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Maliheh Safavi
- Department of Biotechnology, Iranian Research Organization for Science and Technology, P.O. Box 3353-5111, Tehran, Iran
| | - Behjat Pouramiri
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
| | - Alireza Foroumadi
- Drug Design and Development Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
14
|
Engelhardt H, Böse D, Petronczki M, Scharn D, Bader G, Baum A, Bergner A, Chong E, Döbel S, Egger G, Engelhardt C, Ettmayer P, Fuchs JE, Gerstberger T, Gonnella N, Grimm A, Grondal E, Haddad N, Hopfgartner B, Kousek R, Krawiec M, Kriz M, Lamarre L, Leung J, Mayer M, Patel ND, Simov BP, Reeves JT, Schnitzer R, Schrenk A, Sharps B, Solca F, Stadtmüller H, Tan Z, Wunberg T, Zoephel A, McConnell DB. Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. J Med Chem 2019; 62:10272-10293. [PMID: 31689114 DOI: 10.1021/acs.jmedchem.9b01169] [Citation(s) in RCA: 95] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The epidermal growth factor receptor (EGFR), when carrying an activating mutation like del19 or L858R, acts as an oncogenic driver in a subset of lung tumors. While tumor responses to tyrosine kinase inhibitors (TKIs) are accompanied by marked tumor shrinkage, the response is usually not durable. Most patients relapse within two years of therapy often due to acquisition of an additional mutation in EGFR kinase domain that confers resistance to TKIs. Crucially, oncogenic EGFR harboring both resistance mutations, T790M and C797S, can no longer be inhibited by currently approved EGFR TKIs. Here, we describe the discovery of BI-4020, which is a noncovalent, wild-type EGFR sparing, macrocyclic TKI. BI-4020 potently inhibits the above-described EGFR variants and induces tumor regressions in a cross-resistant EGFRdel19 T790M C797S xenograft model. Key was the identification of a highly selective but moderately potent benzimidazole followed by complete rigidification of the molecule through macrocyclization.
Collapse
Affiliation(s)
- Harald Engelhardt
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Dietrich Böse
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Mark Petronczki
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Dirk Scharn
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Gerd Bader
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Anke Baum
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Andreas Bergner
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Eugene Chong
- Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road , Ridgefield , Connecticut 06877 , United States
| | - Sandra Döbel
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Georg Egger
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Christian Engelhardt
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Peter Ettmayer
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Julian E Fuchs
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Thomas Gerstberger
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Nina Gonnella
- Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road , Ridgefield , Connecticut 06877 , United States
| | - Andreas Grimm
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Elisabeth Grondal
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Nizar Haddad
- Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road , Ridgefield , Connecticut 06877 , United States
| | - Barbara Hopfgartner
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Roland Kousek
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Mariusz Krawiec
- Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road , Ridgefield , Connecticut 06877 , United States
| | - Monika Kriz
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Lyne Lamarre
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Joyce Leung
- Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road , Ridgefield , Connecticut 06877 , United States
| | - Moriz Mayer
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Nitinchandra D Patel
- Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road , Ridgefield , Connecticut 06877 , United States
| | - Biljana Peric Simov
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Jonathan T Reeves
- Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road , Ridgefield , Connecticut 06877 , United States
| | - Renate Schnitzer
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Andreas Schrenk
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Bernadette Sharps
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Flavio Solca
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Heinz Stadtmüller
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Zhulin Tan
- Boehringer Ingelheim Pharmaceuticals, Inc. , 900 Ridgebury Road , Ridgefield , Connecticut 06877 , United States
| | - Tobias Wunberg
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Andreas Zoephel
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| | - Darryl B McConnell
- Boehringer Ingelheim RCV GmbH & Co KG , Dr-Boehringer-Gasse 5-11 , Vienna 1120 , Austria
| |
Collapse
|
15
|
Mansour TS, Potluri V, Pallepati RR, Basetti V, Keesara M, Moghudula AG, Maiti P. Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett 2019; 29:1435-1439. [PMID: 31023512 DOI: 10.1016/j.bmcl.2019.04.029] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 04/15/2019] [Accepted: 04/18/2019] [Indexed: 12/11/2022]
Affiliation(s)
- Tarek S Mansour
- Sabila Biosciences LLC, 5 Overlook Road, New City, NY 10956, USA.
| | - Vijay Potluri
- Aurigene Discovery Technology Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, Telangana, India
| | - Ranga R Pallepati
- Aurigene Discovery Technology Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, Telangana, India
| | - Vishnu Basetti
- Aurigene Discovery Technology Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, Telangana, India
| | - Mallaiah Keesara
- Aurigene Discovery Technology Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, Telangana, India
| | - Ashok G Moghudula
- Aurigene Discovery Technology Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, Telangana, India
| | - Pranab Maiti
- Aurigene Discovery Technology Ltd., Bollaram Road, Miyapur, Hyderabad 500 049, Telangana, India
| |
Collapse
|
16
|
Fatima S, Agarwal SM. Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study. J Recept Signal Transduct Res 2018; 38:299-306. [DOI: 10.1080/10799893.2018.1494740] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Shehnaz Fatima
- Bioinformatics Division, ICMR-National Institute of Cancer Prevention and Research, Noida, India
| | - Subhash Mohan Agarwal
- Bioinformatics Division, ICMR-National Institute of Cancer Prevention and Research, Noida, India
| |
Collapse
|
17
|
Young RJ, Leeson PD. Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. J Med Chem 2018; 61:6421-6467. [DOI: 10.1021/acs.jmedchem.8b00180] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- Robert J. Young
- GlaxoSmithKline, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Paul D. Leeson
- Paul Leeson Consulting Ltd., The Malt House, Main Street, Congerstone, Nuneaton, Warwickshire CV13 6LZ, U.K
| |
Collapse
|
18
|
Lu X, Yu L, Zhang Z, Ren X, Smaill JB, Ding K. Targeting EGFRL858R/T790Mand EGFRL858R/T790M/C797Sresistance mutations in NSCLC: Current developments in medicinal chemistry. Med Res Rev 2018; 38:1550-1581. [DOI: 10.1002/med.21488] [Citation(s) in RCA: 71] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 12/19/2017] [Accepted: 12/31/2017] [Indexed: 12/21/2022]
Affiliation(s)
- Xiaoyun Lu
- School of Pharmacy; Jinan University; Guangzhou China
| | - Lei Yu
- Guangzhou Institutes of Biomedicine and Health; Chinese Academy of Sciences; Guangzhou China
| | - Zhang Zhang
- School of Pharmacy; Jinan University; Guangzhou China
| | - Xiaomei Ren
- School of Pharmacy; Jinan University; Guangzhou China
| | - Jeff B. Smaill
- Maurice Wilkins Centre for Molecular Biodiscovery; University of Auckland; Auckland New Zealand
- Auckland Cancer Society Research Centre; University of Auckland; Auckland New Zealand
| | - Ke Ding
- School of Pharmacy; Jinan University; Guangzhou China
| |
Collapse
|